- Antibiotics
- Anti Diarrhea
- Fluids and Electrolyte Replenishers
- Vaccines
- Others
Foodborne Diseases Treatment Market size was valued at USD 9281.2 million in 2022, growing at a CAGR of x% from 2023-29. The foodborne diseases treatment market refers to the healthcare sector focused on diagnosing and treating illnesses and infections caused by the consumption of contaminated or unsafe food. Foodborne diseases, often referred to as food poisoning, can result from the ingestion of bacteria, viruses, parasites, or chemical substances that contaminate food or water. Common pathogens associated with foodborne diseases include Salmonella, E. coli, Campylobacter, Norovirus, and Listeria, among others. These diseases are due to the intake of food contaminated with harmful microorganisms or chemicals. The contamination occurs from any way either soil, water or air. Clinical symptoms of foodborne diseases seen in gastro intestinal tract. Symptoms include vomiting, diarrhea, and abdominal pain. Common foodborne diseases include botulism, salmonellosis, traveler's diarrhoea, gastroenteritis, tapeworm infection and hepatitis A, among others. According to the findings of WHO Estimates of the global burden of foodborne diseases in 2015, almost 1 in every10 people fall ill yearly due to contaminated food consumption and 420,000 deaths occour as a result. Market players are adopting drug developments and collaborations as key market strategies. The report market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).
The Foodborne Diseases Treatment MarketKey Developments :
- In 2015, January, Valneva SE, entered a purchase and sale with Crucell Holland B.V. in order to acquire Crucell Sweden AB and privileges and licenses of dukoral vaccine to treat cholera and traveler's diarrhea.
Global Foodborne Diseases Treatment Market Summary
Study Period
2023-29
Base Year
2022
CAGR
x%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Foodborne Diseases Treatment Market Dynamics
Increase in R&D investment, growing awareness about foodborne disease symptoms due to initiatives of government and non-government organizations such as WHO, and lack of hygiene conditions are boosting the foodborne diseases treatment market worldwide. However, the high cost of R&D investment for development of anti microbial and stringent, time-consuming regulatory procedures are expected to hinder the foodborne diseases market.
Foodborne Diseases Treatment Market Regional Analysis
Foodborne Diseases Treatment Market
Geographically Foodborne Diseases Treatment Market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America foodborne diseases treatment market is expected to grow at notable rates due to increase in the prevalence of foodborne diseases such as botulism and toxoplasmosis, and increase in R&D investment by companies on antibiotics and vaccines. Asia Pacific and Africa regions are projecting lucrative opportunity for foodborne diseases treatment market owing to increase in the incidence of foodborne diseases in these regions. According to WHO estimates 2015, Africa and South East Asia regions have the highest incidence and death rates, including children under the age of 5 years. Europe is expected to show significant growth rate owing to increase in R&D investment and healthcare spending.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Foodborne Diseases Treatment Market Segmentation
By Drug Class
Disease Type
- Botulism
- Traveler's Diarrhea
- Gastroenteritis
- Toxoplasmosis
- Others
Route-Administration
- Parenteral
- Oral
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Frequently Asked Questions
2022 is the base year and 2029 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1.Executive Summary |
| 2.Global Foodborne Diseases Treatment Introduction |
| 2.1.Global Foodborne Diseases Treatment - Taxonomy |
| 2.2.Global Foodborne Diseases Treatment - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Disease Type |
| 2.2.3.Route-Administration |
| 2.2.4.Distribution Channel |
| 2.2.5.Region |
| 3.Global Foodborne Diseases Treatment Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Foodborne Diseases Treatment Analysis, 2018-2022 and Forecast 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Foodborne Diseases Treatment By Drug Class, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 5.1. Antibiotics |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Anti Diarrhea |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Fluids and Electrolyte Replenishers |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Vaccines |
| 5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Foodborne Diseases Treatment By Disease Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 6.1. Botulism |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Traveler's Diarrhea |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Gastroenteritis |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Toxoplasmosis |
| 6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Foodborne Diseases Treatment By Route-Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 7.1. Parenteral |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Oral |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Foodborne Diseases Treatment By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 8.1. Hospital Pharmacies |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacies |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacies |
| 8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Drug Stores |
| 8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 9.Global Foodborne Diseases Treatment By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Foodborne Diseases Treatment ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 10.1. Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Antibiotics |
| 10.1.2.Anti Diarrhea |
| 10.1.3.Fluids and Electrolyte Replenishers |
| 10.1.4.Vaccines |
| 10.1.5.Others |
| 10.2. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Botulism |
| 10.2.2.Traveler's Diarrhea |
| 10.2.3.Gastroenteritis |
| 10.2.4.Toxoplasmosis |
| 10.2.5.Others |
| 10.3. Route-Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Parenteral |
| 10.3.2.Oral |
| 10.3.3.Others |
| 10.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospital Pharmacies |
| 10.4.2.Retail Pharmacies |
| 10.4.3.Online Pharmacies |
| 10.4.4.Drug Stores |
| 10.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Foodborne Diseases Treatment ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Antibiotics |
| 11.1.2.Anti Diarrhea |
| 11.1.3.Fluids and Electrolyte Replenishers |
| 11.1.4.Vaccines |
| 11.1.5.Others |
| 11.2. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Botulism |
| 11.2.2.Traveler's Diarrhea |
| 11.2.3.Gastroenteritis |
| 11.2.4.Toxoplasmosis |
| 11.2.5.Others |
| 11.3. Route-Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Parenteral |
| 11.3.2.Oral |
| 11.3.3.Others |
| 11.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospital Pharmacies |
| 11.4.2.Retail Pharmacies |
| 11.4.3.Online Pharmacies |
| 11.4.4.Drug Stores |
| 11.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 12.Asia Pacific (APAC) Foodborne Diseases Treatment ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Antibiotics |
| 12.1.2.Anti Diarrhea |
| 12.1.3.Fluids and Electrolyte Replenishers |
| 12.1.4.Vaccines |
| 12.1.5.Others |
| 12.2. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Botulism |
| 12.2.2.Traveler's Diarrhea |
| 12.2.3.Gastroenteritis |
| 12.2.4.Toxoplasmosis |
| 12.2.5.Others |
| 12.3. Route-Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Parenteral |
| 12.3.2.Oral |
| 12.3.3.Others |
| 12.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospital Pharmacies |
| 12.4.2.Retail Pharmacies |
| 12.4.3.Online Pharmacies |
| 12.4.4.Drug Stores |
| 12.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Foodborne Diseases Treatment ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Antibiotics |
| 13.1.2.Anti Diarrhea |
| 13.1.3.Fluids and Electrolyte Replenishers |
| 13.1.4.Vaccines |
| 13.1.5.Others |
| 13.2. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Botulism |
| 13.2.2.Traveler's Diarrhea |
| 13.2.3.Gastroenteritis |
| 13.2.4.Toxoplasmosis |
| 13.2.5.Others |
| 13.3. Route-Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Parenteral |
| 13.3.2.Oral |
| 13.3.3.Others |
| 13.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospital Pharmacies |
| 13.4.2.Retail Pharmacies |
| 13.4.3.Online Pharmacies |
| 13.4.4.Drug Stores |
| 13.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Foodborne Diseases Treatment ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 14.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Antibiotics |
| 14.1.2.Anti Diarrhea |
| 14.1.3.Fluids and Electrolyte Replenishers |
| 14.1.4.Vaccines |
| 14.1.5.Others |
| 14.2. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Botulism |
| 14.2.2.Traveler's Diarrhea |
| 14.2.3.Gastroenteritis |
| 14.2.4.Toxoplasmosis |
| 14.2.5.Others |
| 14.3. Route-Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Parenteral |
| 14.3.2.Oral |
| 14.3.3.Others |
| 14.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospital Pharmacies |
| 14.4.2.Retail Pharmacies |
| 14.4.3.Online Pharmacies |
| 14.4.4.Drug Stores |
| 14.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Bayer AG (Germany) |
| 15.2.2.Johnson & Johnson Services Inc., (U.S.) |
| 15.2.3.Merck & Co., Inc. (U.S.) |
| 15.2.4.GlaxoSmithKline plc (U.K) |
| 15.2.5.Novartis AG (Switzerland |
| 15.2.6.XOMA Corporation (U.S.) |
| 15.2.7.AlphaVax, Inc. (U.S.) |
| 15.2.8.Molecular Targeting Technologies, Inc. (U.S.), |
| 15.2.9.Morphotek Inc. (U.S.) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Bayer AG (Germany)
- Johnson & Johnson Services Inc., (U.S.)
- Merck & Co., Inc. (U.S.)
- GlaxoSmithKline plc (U.K)
- Novartis AG (Switzerland
- XOMA Corporation (U.S.)
- AlphaVax, Inc. (U.S.)
- Molecular Targeting Technologies, Inc. (U.S.),
- Morphotek Inc. (U.S.)